Science AI Journal
Medicine · Research topic

Open research questions in Liver Diseases and Immunity

325 gap statements mined from Liver Diseases and Immunity papers in our 7.9M-paper local library, which holds 1,298 papers on the topic — drawn mostly from each paper's own stated research gap, future-work, challenge and limitation notes, and its abstract. The ones listed below are a selection still marked open; each names the study that raised it, with a DOI link where the paper has one.

Choosing where to publish on Liver Diseases and Immunity? See the ranked Medicine journals.

What the literature leaves open

  • Future work will focus on closing the remaining titer gap relative to engineered enzyme cascades and mutant fungal strains through P450FE engineering, host metabolic engineering, and validation in larger bioreactors. Finally, the transferability of the present process-development strategy to other fungal whole-cell steroid biotransformation remains to be experimentally validated.

    Development of a Whole-Cell Bioprocess for Ursodeoxycholic Acid Production from Lithocholic Acid Using Fusarium equiseti HG18 · 2026 · DOI

  • These markers lack specificity as they are frequently detected in other diseases. Furthermore, they are often absent in cases of acute presentation of AIH. The identification and clinical application of disease-specific diagnostic markers are urgent priorities.

    Autoimmune Hepatitis: 2026 Update · 2026 · DOI

  • Regarding pruritus, in PBC it was unrelated to liver stiffness, consistent with reports that pruritus severity does not always correlate with symptoms in this disease, and to our knowledge this relationship has not been examined before.

    Liver Stiffness, Patient-Reported Fatigue, and Pruritus in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: A Cross-Sectional Study · 2026 · DOI

  • Our findings indicate that cholestatic injury is the predominant subtype after PD-1/PD-L1 inhibitor-containing therapy, that the rate of change in liver function parameters has distinctive features across subtypes, and that NLR >3 warrants further investigation as a potential exploratory biomarker for poor recovery.

    Clinical characteristics and prognosis of liver injury in patients receiving immune checkpoint inhibitor-based therapy: a real-world retrospective study · 2026 · DOI

  • Criteria for the diagnosis of canine immune-mediated hepatitis have not been established. (A): CD3-immunopositive lymphocytes are sparse in the liver of the control healthy dog.

    A Case of Canine Hepatitis with Hepatocellular Attack by Non-Neoplastic Perforin-Laden Lymphocytes · 2025 · DOI

  • Patient-reported outcomes should be assessed alongside biochemical and elastographic measures, and how they relate to objective measures of disease remains a major open question that requires new study endpoints.

    Liver Stiffness, Patient-Reported Fatigue, and Pruritus in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: A Cross-Sectional Study · 2026 · DOI

  • For instance, employing known autoantigens to break immune tolerance could be explored to establish a chronic type 2 AIH model.

    Exosome-Modified AAV Gene Therapy Attenuates Autoimmune Hepatitis via Enhanced Regulatory T Cell Targeting and Immune Modulation · 2025 · DOI

  • These findings suggest that VP and MF warrant further investigation as potential therapeutic options for the treatment of PSC.

    The inhibition of YAP Signaling Prevents Chronic Biliary Fibrosis in the Abcb4-/- Model by Modulation of Hepatic Stellate Cell and Bile Duct Epithelium Cell Pathophysiology · 2024 · DOI

  • The prognostic value of magnetic resonance imaging (MRI) in pediatric-onset primary sclerosing cholangitis (PSC) remains poorly studied.

    Prognostic value of magnetic resonance imaging in pediatric-onset primary sclerosing cholangitis · 2026 · DOI

  • The MRI-based ANALI scores with and without gadolinium (ANALI Gd and ANALI NoGd) have predicted disease progression and complications in adults, but these scores have not been studied in children.

    Prognostic value of magnetic resonance imaging in pediatric-onset primary sclerosing cholangitis · 2026 · DOI

  • However, robust long-term data on clinical outcomes such as liver transplantation or survival remains lacking for all agents.

    Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor · 2025 · DOI

  • However, the available observational study evidence results are inconsistent, and causality is unclear.

    Causal Association of Primary Biliary Cholangitis with Adverse Pregnancy and Neonatal Outcomes: A Two-Sample Mendelian Randomization Study · 2025 · DOI

  • While MMP-7 has emerged as a promising biomarker for fibrosis in hepatocyte-centric diseases like NAFLD, its role in PBC—a disease centered on biliary injury—remains poorly defined.

    Serum matrix metalloproteinase-7 as a diagnostic and prognostic biomarker in primary biliary cholangitis · 2026 · DOI

  • The current criterion of biochemical response to UDCA is an ALP level of ≤1.67 × ULN after 12 months of treatment, but this may not be sufficient to identify patients at risk of poor outcomes. There is a need to establish ALP normalization as a core treatment target and identify early intervention windows for treatment.

    A Dual Time Window-driven Strategy to Optimize Primary Biliary Cholangitis Treatment via Alkaline Phosphatase Normalization · 2026 · DOI

  • There is a lack of effective drug treatment regimens for PSC in clinical practice. The diagnosis and treatment of PSC-UC are challenging due to the rarity of the condition.

    Primary sclerosing cholangitis complicated with ulcerative colitis and double gene mutations of UGT1A1 and SLC25A13: a case report · 2026 · DOI

  • There is a lack of effective drug treatment regimens for PSC in clinical practice. The pathogenesis of PSC-UC is not fully understood, and the role of genetic susceptibility is unclear.

    Primary sclerosing cholangitis complicated with ulcerative colitis and double gene mutations of UGT1A1 and SLC25A13: a case report · 2026 · DOI

  • Inflammatory and fibrogenic stimuli, such as transforming growth factor-{beta} (TGF{beta}) and lipopolysaccharide (LPS) signaling, drive these processes, but their underlying transcriptional mechanisms in cholangiocytes remain incompletely defined.

    Cholangiocyte RUNX1 Orchestrates Fibrogenic and Inflammatory Signaling to Drive Biliary Fibrosis · 2026 · DOI

  • The randomized controlled trials included in the constituent meta-analyses had relatively short follow-up periods (mean duration 8–39 months), which are insufficient to capture differences in hard clinical endpoints such as mortality or liver transplantation.

    Comparative efficacy and safety of ursodeoxycholic acid, fibrates, and combination therapy in primary biliary cholangitis: an umbrella meta-analysis of meta-analyses · 2026 · DOI

  • The underlying mechanisms and triggers of AIH have not yet been clarified. The pathogenesis of AIH is not yet fully understood.

    Hepatitis A virus-induced autoimmune hepatitis: A case-based review · 2026 · DOI

  • The pathogenesis of PBC remains incompletely understood. The study aims to address the gap in knowledge regarding the genetic mechanisms of PBC.

    Genetic mechanisms of primary biliary cholangitis and its association with immune cells using mendelian randomization and biological annotation · 2026 · DOI

  • The need to understand the contributions of T-cell activity and autoantibody production to immune-mediated liver damage. The requirement for therapeutic strategies for autoimmune liver diseases.

    Process Flow Outlining the Mechanisms of Immune-Mediated Liver Damage: Comprehensive Analysis of T-Cell Activity and Autoantibody Contributions in Hepatocellular Injury · 2026 · DOI

  • Primary biliary cholangitis (PBC) with early cholestasis and extensive bile duct loss but no significant fibrosis or cirrhosis is rare and underrecognized.

    Clinicopathologic Features of a Rare and Underrecognized Variant of Early-stage Primary Biliary Cholangitis With Ductopenia · 2024 · DOI

  • Liver diseases often develop gradually and may remain asymptomatic for a long time. Many patients are diagnosed at advanced stages, when structural and functional liver damage is already pronounced. The immune system plays a direct role in hepatocellular injury in autoimmune and immune-mediated liver diseases.

    THE IMPORTANCE OF IMMUNODIAGNOSTICS IN THE DIAGNOSIS OF LIVER DISEASES IN MODERN MEDICINE · 2026 · DOI

  • Only cells from non-responder end-stage patients were available for liver NK cell analysis, - The study used a relatively small sample size, - The analysis was limited to PBMCs and liver…

    Immune profiling identifies dysregulated natural killer-cell responses in primary biliary cholangitis patients who fail treatment with ursodeoxycholic acid · 2026 · DOI

  • Investigating the role of NK cells in PBC pathogenesis, - Analyzing the transcriptomic profile of NK cells in PBC patients, - Studying the effects of UDCA treatment on NK cell…

    Immune profiling identifies dysregulated natural killer-cell responses in primary biliary cholangitis patients who fail treatment with ursodeoxycholic acid · 2026 · DOI

Most-cited papers in Liver Diseases and Immunity

Most recent work

Find a gap in your own Liver Diseases and Immunity sub-topic

This page shows what the Liver Diseases and Immunity literature already flags as unresolved. To narrow it to your specific question, search the Research Gap Finder: the search is free with a free account and lists the papers closest to your topic first. Unlocking that topic (50 credits, charged once) fills the comparison table from our 7.9M-paper local library and writes the gaps from its rows.

Open the Research Gap Finder →

Related topics in Medicine

Artificial Intelligence in Healthcare and Education
4,869 open questions
Dementia and Cognitive Impairment Research
3,297 open questions
Cancer Immunotherapy and Biomarkers
2,687 open questions
Liver Disease Diagnosis and Treatment
2,481 open questions
Substance Abuse Treatment and Outcomes
2,366 open questions
Sports Performance and Training
2,276 open questions
Mosquito-borne diseases and control
2,124 open questions
Parkinson's Disease Mechanisms and Treatments
2,117 open questions
Open questions raised by papers listed on this page include: (1) Future work will focus on closing the remaining titer gap relative to engineered enzyme cascades and mutant fungal strains through P450FE engineering, host metabolic engineering, and validation in larger bioreactors (“Development of a Whole-Cell Bioprocess for Ursodeoxycholic Acid Production from…”, 2026); (2) Patient-reported outcomes should be assessed alongside biochemical and elastographic measures, and how they relate to objective measures of disease remains a major open question that requires new study endpoints (“Liver Stiffness, Patient-Reported Fatigue, and Pruritus in Primary Biliary…”, 2026); (3) The MRI-based ANALI scores with and without gadolinium (ANALI Gd and ANALI NoGd) have predicted disease progression and complications in adults, but these scores have not been studied in children (“Prognostic value of magnetic resonance imaging in pediatric-onset primary…”, 2026); (4) There is a need to establish ALP normalization as a core treatment target and identify early intervention windows for treatment (“A Dual Time Window-driven Strategy to Optimize Primary Biliary Cholangitis…”, 2026); (5) There is a lack of effective drug treatment regimens for PSC in clinical practice (“Primary sclerosing cholangitis complicated with ulcerative colitis and double…”, 2026). 325 gap statements have been mined from Liver Diseases and Immunity papers in our 7.9M-paper local library, which holds 1,298 papers on the topic; the gaps come from whichever of those papers state one. They are mostly the research gaps the authors state and the papers' abstracts, plus future-work, limitations and challenges passages. The ones listed below are a selection still marked open; each names the study that raised it, with a DOI link where the paper has one, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 1,100,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? Acceptance odds for top, mid and open/emerging journals, in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck for prior publication across 7 sources and our local library.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

How Pre-Check worksHow AI Review works

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.